Physician profile
Nicholas Crowley
NPI 1114331949
$6,551.66
in general payments reported to CMS, 2019-2025
30 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $439 · 2021: $154 · 2022: $1,199 · 2023: $1,019 · 2024: $870 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,993.95 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $503.78 | 2019-2025 | |
| Biofrontera INC. | $473.02 | 2019 | |
| Pfizer INC. | $394.19 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $334.09 | 2019-2025 | Blu-U |
| Ucb, INC. | $328.46 | 2022-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $290.07 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $235.14 | 2019-2022 | |
| Incyte Corporation | $234.92 | 2024-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $225.29 | 2020-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $216.40 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $201.13 | 2019-2025 | Ebglyss, Taltz |
| Celgene Corporation | $165.61 | 2019 | |
| Almirall LLC | $148.92 | 2019-2025 | Seysara, Klisyri |
| Leo Pharma INC. | $143.83 | 2019-2024 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $135.57 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $115.92 | 2019-2025 | Nemluvio |
| Musculoskeletal Transplant Foundation INC. | $67.69 | 2019 | |
| Mayne Pharma Commercial LLC | $66.22 | 2020-2025 | |
| Genzyme Corporation | $53.85 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.65 | 2019-2025 | Cabtreo |
| Vyne Pharmaceuticals INC. | $33.34 | 2020 | |
| Amgen INC. | $26.84 | 2022-2024 | Otezla |
| Journey Medical Corporation | $20.68 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.79 | 2019 | |
| Epi Health, LLC | $18.98 | 2019 | |
| Botanix Sb INC | $17.06 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $15.29 | 2025 | Ycanth |
| Krystal Biotech INC | $12.79 | 2023 | Vyjuvek |
| Organon LLC | $12.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.